These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 34736870)
1. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870 [TBL] [Abstract][Full Text] [Related]
2. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database. Park CL; Moria FA; Ghosh S; Wood L; Bjarnason GA; Bhindi B; Heng DYC; Castonguay V; Pouliot F; Kollmannsberger CK; Bosse D; Basappa NS; Finelli A; Fallah-Rad N; Breau RH; Lalani AA; Tanguay S; Graham J; Saleh RR Curr Oncol; 2024 Aug; 31(8):4704-4712. PubMed ID: 39195334 [TBL] [Abstract][Full Text] [Related]
3. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622 [TBL] [Abstract][Full Text] [Related]
5. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579 [TBL] [Abstract][Full Text] [Related]
6. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies. Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481 [TBL] [Abstract][Full Text] [Related]
7. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962 [TBL] [Abstract][Full Text] [Related]
8. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943 [TBL] [Abstract][Full Text] [Related]
10. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070 [TBL] [Abstract][Full Text] [Related]
11. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm. Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483 [TBL] [Abstract][Full Text] [Related]
12. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach. Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610 [TBL] [Abstract][Full Text] [Related]
13. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial. Park JS; Kim J; Jeon J; Lee J; Jang WS; Lee SH; Han WK; Choi YD; Koo KC; Cho KS; Chung BH; Ham WS Trials; 2024 Jul; 25(1):447. PubMed ID: 38961439 [TBL] [Abstract][Full Text] [Related]
14. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123 [TBL] [Abstract][Full Text] [Related]
15. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis. Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574 [TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Graham J; Wells JC; Donskov F; Lee JL; Fraccon A; Pasini F; Porta C; Bowman IA; Bjarnason GA; Ernst DS; Rha SY; Beuselinck B; Hansen A; North SA; Kollmannsberger CK; Wood LA; Vaishampayan UN; Pal SK; Choueiri TK; Heng DYC Eur Urol Oncol; 2019 Nov; 2(6):643-648. PubMed ID: 31411994 [TBL] [Abstract][Full Text] [Related]
17. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526 [TBL] [Abstract][Full Text] [Related]
18. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis. Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696 [TBL] [Abstract][Full Text] [Related]
19. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729 [TBL] [Abstract][Full Text] [Related]
20. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]